Name
OÜ X7 Clinicals and Pharmaceuticals Research EU
Registry code
14119880
VAT number
EE102168471
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
26.09.2016 (8)
Financial year
01.01-31.12
Capital
2 500.00 €
Activity
72191 - Other research and experimental development on natural sciences and engineering
163 220 €
-12 772 €
-8%
-
13 453 €
0
Submitted
No tax arrears
-95%
-9%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Tatjana Semõkina 18.08.1975 (49) | 100% - 2 500.00 EUR | Board member | Direct ownership | |
| Olga Lembinen 15.03.1976 (48) | - | Board member | - |
| 2019 12.10.2020 | 2020 11.06.2021 | 2021 15.04.2022 | 2022 26.05.2023 | 2023 01.03.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 33 577 € | 19 542 € | 107 812 € | 137 344 € | 163 220 € |
| Net profit (loss) for the period | -1 834 € | 2 471 € | 45 563 € | -23 099 € | -12 772 € |
| Profit Margin | -5% | 13% | 42% | -17% | -8% |
| Current Assets | 34 937 € | 14 533 € | 66 137 € | 169 442 € | 138 314 € |
| Fixed Assets | - | - | - | - | - |
| Total Assets | 34 937 € | 14 533 € | 66 137 € | 169 442 € | 138 314 € |
| Current Liabilities | 31 147 € | 8 272 € | 14 313 € | 4 334 € | 4 334 € |
| Non Current Liabilities | - | - | - | 138 883 € | 120 527 € |
| Total Liabilities | - | - | - | 143 217 € | 124 861 € |
| Share Capital | - | - | - | - | - |
| Equity | 3 790 € | 6 261 € | 51 824 € | 26 225 € | 13 453 € |
| Employees | 0 | 0 | 0 | 0 | 0 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 49 655.2 € | - | - | - |
| 2023 Q4 | 96 651.5 € | - | - | - |
| 2023 Q3 | 7 999 € | - | - | - |
| 2023 Q2 | 5 038 € | - | - | - |
| 2023 Q1 | 22 127.28 € | - | - | - |
| 2022 Q4 | 68 702 € | - | - | - |
| 2022 Q3 | - | - | - | - |
| 2022 Q2 | 56 132.9 € | - | - | - |
| 2022 Q1 | 28 804 € | - | - | - |
| 2021 Q4 | 70 316.61 € | - | - | - |
| 2021 Q3 | 3 804 € | - | - | - |
| 2021 Q2 | 19 467 € | - | - | - |
| 2021 Q1 | - | - | - | - |
| 2020 Q4 | - | - | - | - |
| 2020 Q3 | - | - | - | - |
| 2020 Q2 | 8 943.88 € | 40 € | - | - |
| 2020 Q1 | 11 698.25 € | - | - | - |
